Research Peptide Blog Database
Peer-reviewed studies, clinical data, mechanism breakdowns, and molecular specifications — all in one place.
GHRH Analog · Visceral Fat Research Compound
Tesamorelin
GHRH analog. For in vitro research use only.
Published Scientific Research
Peer-reviewed studies investigating Tesamorelin sourced from PubMed-indexed journals for educational reference only.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay...
View Full Study on PubMed →Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been...
View Full Study on PubMed →Growth hormone in the aging male.
Secretion of growth hormone (GH) and IGF-1 levels decline during advancing years-of-life. These changes (somatopause) are associated with loss of vitality, muscle mass, physical function, together with the occurrence of frailty, central adiposity, cardiovascular complications,...
View Full Study on PubMed →Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
Strategies to augment pulsatile GH may be beneficial in patients with excess visceral adiposity, in whom GH secretion is reduced. The objective of this study was to determine the effects of a novel GHRH (GHRH(1-44))...
View Full Study on PubMed →Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in this population. We investigated the effects of tesamorelin (GHRH(1-44)) in HIV-infected patients with central...
View Full Study on PubMed →Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
HIV patients treated with antiretroviral therapy (ART) often develop increased visceral adipose tissue (VAT).
View Full Study on PubMed →Pathogenesis and treatment of HIV lipohypertrophy.
This review addresses our current understanding of the pathogenesis of HIV-associated lipohypertrophy and describes an evidence-based approach to treatment.
View Full Study on PubMed →Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
HIV-associated lipodystrophy is a disorder of fat metabolism that occurs in patients with HIV infection. It can cause metabolic derangements and negative self-perceptions of body image, and result in noncompliance with highly active antiretroviral therapy...
View Full Study on PubMed →Technical Specifications
🔬 Molecular Profile
🧊 Storage Requirements
Research-Grade Tesamorelin
≥98% purity, third-party COA verified, lyophilized for stability. For in vitro laboratory research use only.
⚠️ Important Research Notice
All compounds listed are intended exclusively for in vitro laboratory research by qualified professionals. Not for human or animal consumption. Not approved by the FDA for any diagnostic, therapeutic, or clinical purpose. All research findings are sourced from peer-reviewed journals for educational reference only. Not to be interpreted as medical advice or product claims.